Clinical, laboratory and molecular findings and long-term follow-up data in 96 French patients with PMM2-CDG (phosphomannomutase 2-congenital disorder of glycosylation) and review of the literature
- PMID: 28954837
- DOI: 10.1136/jmedgenet-2017-104903
Clinical, laboratory and molecular findings and long-term follow-up data in 96 French patients with PMM2-CDG (phosphomannomutase 2-congenital disorder of glycosylation) and review of the literature
Abstract
Background: Phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG) is a multisystem inborn error of metabolism.
Objectives: To better characterise the natural history of PMM2-CDG.
Methods: Medical charts of 96 patients with PMM2-CDG (86 families, 41 males, 55 females) were retrospectively reviewed. Data on clinical, laboratory and molecular parameters at diagnosis were analysed. Follow-up data at last examination were reported for 25 patients.
Results: The patients were born between 1963 and 2011. Diagnosis of PMM2-CDG was made at a mean (SD) age of 6.8 (8.5) years. The presenting signs were mostly neurological (hypotonia, intellectual disability, cerebellar syndrome) and observed in almost all the patients. A total of 38 patients (14 males, 24 females) exhibited, in addition to neurological signs, visceral features including at least one of these: feeding difficulty requiring a nutritional support (n=23), cardiac features (n=20; pericarditis: 14, cardiac malformation: 9, cardiomyopathy: 2), hepato-gastrointestinal features (n=12; chronic diarrhoea: 7, protein-losing enteropathy: 1, ascites: 3, liver failure: 1, portal hypertension: 1), kidney features (n=4; nephrotic syndrome: 2, tubulopathy: 2) and hydrops fetalis (n=1). Twelve patients died at a mean age of 3.8 years (especially from pericarditis and other cardiac issues). Laboratory abnormalities mostly included elevated transaminases and abnormal coagulation parameters. High thyreostimulin levels, hypocholesterolemia, hypoalbuminemia and elevated transaminases were associated with the visceral phenotype. Besides the common Arg141His PMM2 variant harboured by half of the patients, 45 different variants were observed.
Conclusions: PMM2-CDG clinical phenotype is heterogeneous in terms of clinical course, with no clear division between neurological and visceral presentations.
Keywords: CDG-I; PMM2-CDG; congenital disorders of glycosylation; phosphomannomutase.
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Conflict of interest statement
Competing interests: None declared.
Similar articles
-
29 French adult patients with PMM2-congenital disorder of glycosylation: outcome of the classical pediatric phenotype and depiction of a late-onset phenotype.Orphanet J Rare Dis. 2014 Dec 11;9:207. doi: 10.1186/s13023-014-0207-4. Orphanet J Rare Dis. 2014. PMID: 25497157 Free PMC article.
-
The Analysis of Variants in the General Population Reveals That PMM2 Is Extremely Tolerant to Missense Mutations and That Diagnosis of PMM2-CDG Can Benefit from the Identification of Modifiers.Int J Mol Sci. 2018 Jul 30;19(8):2218. doi: 10.3390/ijms19082218. Int J Mol Sci. 2018. PMID: 30061496 Free PMC article.
-
Renal involvement in PMM2-CDG, a mini-review.Mol Genet Metab. 2018 Mar;123(3):292-296. doi: 10.1016/j.ymgme.2017.11.012. Epub 2017 Nov 28. Mol Genet Metab. 2018. PMID: 29229467 Review.
-
Neurodevelopmental profiles of 14 individuals with phosphomannomutase deficiency (PMM2-CDG).J Inherit Metab Dis. 2025 Jan;48(1):e12782. doi: 10.1002/jimd.12782. Epub 2024 Aug 6. J Inherit Metab Dis. 2025. PMID: 39105373 Free PMC article.
-
International clinical guidelines for the management of phosphomannomutase 2-congenital disorders of glycosylation: Diagnosis, treatment and follow up.J Inherit Metab Dis. 2019 Jan;42(1):5-28. doi: 10.1002/jimd.12024. J Inherit Metab Dis. 2019. PMID: 30740725
Cited by
-
Yeast Models of Phosphomannomutase 2 Deficiency, a Congenital Disorder of Glycosylation.G3 (Bethesda). 2019 Feb 7;9(2):413-423. doi: 10.1534/g3.118.200934. G3 (Bethesda). 2019. PMID: 30530630 Free PMC article.
-
Instrumented assessment of gait disturbance in PMM2-CDG adults: a feasibility analysis.Orphanet J Rare Dis. 2024 Feb 2;19(1):39. doi: 10.1186/s13023-024-03027-x. Orphanet J Rare Dis. 2024. PMID: 38308356 Free PMC article.
-
Multimodal insights into adult neurogenesis: An integrative review of multi-omics approaches.Heliyon. 2025 Feb 13;11(4):e42668. doi: 10.1016/j.heliyon.2025.e42668. eCollection 2025 Feb 28. Heliyon. 2025. PMID: 40051854 Free PMC article. Review.
-
Clinical and biochemical footprints of inherited metabolic disease. XVI. Hematological abnormalities.Mol Genet Metab. 2023 Dec;140(4):107735. doi: 10.1016/j.ymgme.2023.107735. Epub 2023 Nov 13. Mol Genet Metab. 2023. PMID: 37989003 Free PMC article. Review.
-
Phosphomannomutase 2 (PMM2) variants leading to hyperinsulinism-polycystic kidney disease are associated with early-onset inflammatory bowel disease and gastric antral foveolar hyperplasia.Hum Genet. 2023 May;142(5):697-704. doi: 10.1007/s00439-023-02523-7. Epub 2023 Feb 11. Hum Genet. 2023. PMID: 36773065 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources